The purpose of the study is to see if this step‑by‑step approach can improve outcomes for people with this high‑risk lymphoma. Participants will receive the initial combination of glofitamab plus chemotherapy in several treatment cycles, then undergo infusion of a CAR‑T product such as Breyanzi or Yescarta, and finally receive further glofitamab doses as consolidation. The whole sequence takes place over several months, with regular clinic visits for infusions, monitoring, and safety checks.

Throughout the trial, doctors will watch for any side effects, assess how well the disease responds, and evaluate overall health and quality of life. Follow‑up continues after the last treatment to see how long the response lasts and to track any late‑appearing effects.

The medications will be given in different ways – some as tablets taken by mouth and others through an intravenous infusion (given directly into a vein) or subcutaneous injection (given under the skin). The study will be conducted in two parts. The first part will determine the right dose of the drug combinations, while the second part will further study how well these doses work and what side effects they may cause.

Throughout the study, doctors will monitor patients’ health, check how well the treatment is working, and track any side effects. They will look at how many patients respond to treatment and how long the response lasts. For some patients, they will also measure the amount of cancer cells remaining in the blood or bone marrow after treatment.

The purpose of the study is to learn how well AZD0486 works and how safe it is for patients with this type of cancer. Participants in the study will receive the treatment through an intravenous infusion, which means the medicine will be given directly into a vein. The study will follow participants over time to see how their cancer responds to the treatment and to monitor any side effects they might experience.

Throughout the study, researchers will collect information on how the treatment affects the cancer and the overall health of the participants. This includes looking at changes in the size of the cancer, any improvements in symptoms, and any side effects that occur. The study aims to provide valuable information that could lead to new treatment options for people with Non-Hodgkin Lymphoma.

The trial involves several medications, including Cytarabine, Tafasitamab (also known as MOR00208), Lenalidomide, Dexamethasone, Cisplatin, Bendamustine Hydrochloride, Polatuzumab Vedotin (also known as RO5541077), and Rituximab. These medications are used in various forms such as solutions for infusion, injections, and capsules. Some patients may receive a placebo as part of the study. The study will monitor the overall response rate to the second-line treatment and any significant side effects that may occur.

Participants in the study will undergo regular assessments, including blood tests to measure circulating tumor DNA and imaging tests like PET-CT scans to monitor disease progression. The study will also evaluate the quality of life of participants using a specific questionnaire. The trial is expected to continue until early 2026, with the goal of improving treatment strategies for patients with these types of lymphomas.

The purpose of the study is to compare how well patients respond to the treatment with and without Selinexor. The study is divided into two phases. In the first phase, the focus is on how many patients show a positive response to the treatment. In the second phase, the study looks at how long patients live without the disease getting worse. Some patients will receive a placebo, which is a tablet that looks like the real medication but does not contain the active drug, to compare the effects of the actual treatment.

Participants in the study will receive the treatment over a period of time, and their health will be monitored to see how the disease responds. The study aims to provide more information on whether adding Selinexor to the existing treatment can improve outcomes for patients with RR DLBCL. This research could help in developing better treatment strategies for this type of lymphoma in the future.

The study is divided into different groups. One group will receive Mosunetuzumab after their initial treatment to see if it helps in maintaining their response to the first treatment. Another group will include elderly or less fit patients who have not been treated for DLBCL before, and they will receive Mosunetuzumab either alone or in combination with Polatuzumab Vedotin. The study will monitor how well the treatments work in reducing the cancer and how safe they are for the patients.

Participants in the study will receive the treatments through intravenous (IV) infusion or subcutaneous injection, depending on the group they are in. The study will track the response of the cancer to the treatment using imaging techniques and will also keep an eye on any side effects that may occur. The goal is to find the best dose and combination of these medications to help patients with DLBCL.

The medications being tested are both types of targeted therapies. Mosunetuzumab is a specially designed antibody that helps the immune system recognize and attack cancer cells. Polatuzumab vedotin is a medication that combines an antibody with a substance that kills cancer cells. The study will test these medications given together through intravenous infusion or as an injection under the skin.

The study will check if this combination of medications is safe to use and how well it works in treating the lymphoma. Researchers will monitor patients for side effects and measure if the cancer responds to the treatment. The study will also look at how long any improvements last and how the medications move through the body. Additional medications may be given to help manage side effects, including prednisone, dexamethasone, paracetamol, and other supportive care medicines.

Participants in the study will receive the treatments through an intravenous infusion, which means the medication is given directly into the bloodstream. The study will monitor how the body responds to the treatment over a period of time, looking at factors such as how well the cancer responds and any side effects that may occur. The study will also explore how the treatment affects the immune system and how long the modified cells remain active in the body.

This trial is an important step in understanding how these new therapies can help people with Large B-Cell Lymphoma who have limited treatment options. By participating, researchers hope to gather valuable information that could lead to new and effective treatments for this type of cancer in the future.

The purpose of the study is to see how effective the combination of these medications is in helping the body accept the CAR T cell therapy and to compare it to the use of Fludarabine and Cyclophosphamide alone. Participants in the study will receive either the combination of Fludarabine, Cyclophosphamide, and ALLO-647 or just Fludarabine and Cyclophosphamide before receiving the ALLO-501A therapy. The study will monitor how well the cancer responds to the treatment and how long the response lasts. It will also look at the safety of the treatment and any side effects that may occur.

The study will take place over a period of time, with participants receiving treatment and being monitored for their response to the therapy. The goal is to gather information that could help improve treatment options for people with relapsed or refractory Large B-Cell Lymphoma. This research could potentially lead to new ways to treat this type of cancer more effectively in the future.